Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC

Shirish Gadgeel, Alice T. Shaw, Fabrice Barlesi, Lucio Crinò, James Chih Hsin Yang, Anne Marie C. Dingemans, Dong Wan Kim, Filippo De Marinis, Mathias Schulz, Shiyao Liu, Ravindra Gupta, Ahmed Kotb, Sai Hong Ignatius Ou

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background:We evaluated the cumulative incidence rate (CIR) of central nervous system (CNS) and non-CNS progression in alectinib-treated patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) to determine the extent to which alectinib may treat or control CNS disease.Methods:Patients with crizotinib-pretreated locally advanced or metastatic disease received alectinib 600 mg orally twice daily in two phase II trials. All patients underwent baseline imaging and regular centrally reviewed scans.Results:At 24 months, the CIR for CNS progression was lower in patients without vs with baseline CNS metastases (8.0 vs 43.9%). Patients with baseline CNS disease and prior radiotherapy had a higher CIR of CNS progression than radiotherapy-naive patients (50.5 vs 27.4%) and a lower CIR of non-CNS progression (25.8 vs 42.5%). Adverse events leading to withdrawal occurred in 5.9% and 6.7% of patients with and without baseline CNS metastases, respectively.Conclusions:This analysis indicates a potential role for alectinib in controlling and preventing CNS metastases.

Original languageEnglish
Pages (from-to)38-42
Number of pages5
JournalBritish Journal of Cancer
Volume118
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Non-Small Cell Lung Carcinoma
Nervous System
Central Nervous System
Incidence
Central Nervous System Diseases
Neoplasm Metastasis
Radiotherapy
anaplastic lymphoma kinase
CH5424802

Keywords

  • alectinib
  • ALK positive
  • central nervous system
  • cumulative incidence rates
  • disease progression
  • non-small-cell lung cancer
  • phase II

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC. / Gadgeel, Shirish; Shaw, Alice T.; Barlesi, Fabrice; Crinò, Lucio; Yang, James Chih Hsin; Dingemans, Anne Marie C.; Kim, Dong Wan; De Marinis, Filippo; Schulz, Mathias; Liu, Shiyao; Gupta, Ravindra; Kotb, Ahmed; Ou, Sai Hong Ignatius.

In: British Journal of Cancer, Vol. 118, No. 1, 01.01.2018, p. 38-42.

Research output: Contribution to journalArticle

Gadgeel, S, Shaw, AT, Barlesi, F, Crinò, L, Yang, JCH, Dingemans, AMC, Kim, DW, De Marinis, F, Schulz, M, Liu, S, Gupta, R, Kotb, A & Ou, SHI 2018, 'Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC', British Journal of Cancer, vol. 118, no. 1, pp. 38-42. https://doi.org/10.1038/bjc.2017.395
Gadgeel, Shirish ; Shaw, Alice T. ; Barlesi, Fabrice ; Crinò, Lucio ; Yang, James Chih Hsin ; Dingemans, Anne Marie C. ; Kim, Dong Wan ; De Marinis, Filippo ; Schulz, Mathias ; Liu, Shiyao ; Gupta, Ravindra ; Kotb, Ahmed ; Ou, Sai Hong Ignatius. / Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC. In: British Journal of Cancer. 2018 ; Vol. 118, No. 1. pp. 38-42.
@article{c3deb97cc4854dfa87b1fc72a316514b,
title = "Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC",
abstract = "Background:We evaluated the cumulative incidence rate (CIR) of central nervous system (CNS) and non-CNS progression in alectinib-treated patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) to determine the extent to which alectinib may treat or control CNS disease.Methods:Patients with crizotinib-pretreated locally advanced or metastatic disease received alectinib 600 mg orally twice daily in two phase II trials. All patients underwent baseline imaging and regular centrally reviewed scans.Results:At 24 months, the CIR for CNS progression was lower in patients without vs with baseline CNS metastases (8.0 vs 43.9{\%}). Patients with baseline CNS disease and prior radiotherapy had a higher CIR of CNS progression than radiotherapy-naive patients (50.5 vs 27.4{\%}) and a lower CIR of non-CNS progression (25.8 vs 42.5{\%}). Adverse events leading to withdrawal occurred in 5.9{\%} and 6.7{\%} of patients with and without baseline CNS metastases, respectively.Conclusions:This analysis indicates a potential role for alectinib in controlling and preventing CNS metastases.",
keywords = "alectinib, ALK positive, central nervous system, cumulative incidence rates, disease progression, non-small-cell lung cancer, phase II",
author = "Shirish Gadgeel and Shaw, {Alice T.} and Fabrice Barlesi and Lucio Crin{\`o} and Yang, {James Chih Hsin} and Dingemans, {Anne Marie C.} and Kim, {Dong Wan} and {De Marinis}, Filippo and Mathias Schulz and Shiyao Liu and Ravindra Gupta and Ahmed Kotb and Ou, {Sai Hong Ignatius}",
year = "2018",
month = "1",
day = "1",
doi = "10.1038/bjc.2017.395",
language = "English",
volume = "118",
pages = "38--42",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC

AU - Gadgeel, Shirish

AU - Shaw, Alice T.

AU - Barlesi, Fabrice

AU - Crinò, Lucio

AU - Yang, James Chih Hsin

AU - Dingemans, Anne Marie C.

AU - Kim, Dong Wan

AU - De Marinis, Filippo

AU - Schulz, Mathias

AU - Liu, Shiyao

AU - Gupta, Ravindra

AU - Kotb, Ahmed

AU - Ou, Sai Hong Ignatius

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background:We evaluated the cumulative incidence rate (CIR) of central nervous system (CNS) and non-CNS progression in alectinib-treated patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) to determine the extent to which alectinib may treat or control CNS disease.Methods:Patients with crizotinib-pretreated locally advanced or metastatic disease received alectinib 600 mg orally twice daily in two phase II trials. All patients underwent baseline imaging and regular centrally reviewed scans.Results:At 24 months, the CIR for CNS progression was lower in patients without vs with baseline CNS metastases (8.0 vs 43.9%). Patients with baseline CNS disease and prior radiotherapy had a higher CIR of CNS progression than radiotherapy-naive patients (50.5 vs 27.4%) and a lower CIR of non-CNS progression (25.8 vs 42.5%). Adverse events leading to withdrawal occurred in 5.9% and 6.7% of patients with and without baseline CNS metastases, respectively.Conclusions:This analysis indicates a potential role for alectinib in controlling and preventing CNS metastases.

AB - Background:We evaluated the cumulative incidence rate (CIR) of central nervous system (CNS) and non-CNS progression in alectinib-treated patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) to determine the extent to which alectinib may treat or control CNS disease.Methods:Patients with crizotinib-pretreated locally advanced or metastatic disease received alectinib 600 mg orally twice daily in two phase II trials. All patients underwent baseline imaging and regular centrally reviewed scans.Results:At 24 months, the CIR for CNS progression was lower in patients without vs with baseline CNS metastases (8.0 vs 43.9%). Patients with baseline CNS disease and prior radiotherapy had a higher CIR of CNS progression than radiotherapy-naive patients (50.5 vs 27.4%) and a lower CIR of non-CNS progression (25.8 vs 42.5%). Adverse events leading to withdrawal occurred in 5.9% and 6.7% of patients with and without baseline CNS metastases, respectively.Conclusions:This analysis indicates a potential role for alectinib in controlling and preventing CNS metastases.

KW - alectinib

KW - ALK positive

KW - central nervous system

KW - cumulative incidence rates

KW - disease progression

KW - non-small-cell lung cancer

KW - phase II

UR - http://www.scopus.com/inward/record.url?scp=85040316540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040316540&partnerID=8YFLogxK

U2 - 10.1038/bjc.2017.395

DO - 10.1038/bjc.2017.395

M3 - Article

VL - 118

SP - 38

EP - 42

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 1

ER -